Clinical Trial Update: Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 biomarker study assessing the immune-mediated mechanism of action of neoadjuvant trastuzumab in HER2-positive breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Cancer, Breast | Phase 2 | Status: UNKNOWN